AUR-109

N/A

Report date: 2026/04/18 20:00:19
NME

Base Information

Drug NameAUR-109
Drug Alias NameODM-203AUR-109
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 1 antagonistsFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 3 antagonists +[7] 
TargetsFibroblast growth factor receptor 1Fibroblast growth factor receptor 2Fibroblast growth factor receptor 3 +[7] 
Therapy Area/IndicationsSolid tumoursPulmonary FibrosisUrinary Bladder Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyDenmarkUnited Kingdom +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOrion Corp
China Registration ClassN/A

Develop Information

Active CompaniesAurigene Oncology Ltd
Inactive CompaniesAurigene Discovery Technologies LtdOrion Corporation Orion Pharma
Active IndicationsPulmonary FibrosisUrinary Bladder NeoplasmsLung Neoplasms +[7] 
Inactive IndicationsSolid tumoursKidney NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A